Jazz Pharmaceuticals, Inc. drugs

9 results

  • defitelio

    (defibrotide sodium)
    Jazz Pharmaceuticals, Inc.
    DEFITELIO is indicated for treating adult and pediatric patients with hepatic veno-occlusive disease (VOD), or sinusoidal obstruction syndrome (SOS), accompanied by renal or pulmonary dysfunction after hematopoietic stem-cell transplantation (HSCT).
    Medication Details
    Drug Interactions

  • epidiolex

    (cannabidiol)
    Jazz Pharmaceuticals, Inc.
    EPIDIOLEX is indicated for treating seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients aged 1 year and older.
    Medication Details
    Drug Interactions

  • modeyso

    (dordaviprone)
    Jazz Pharmaceuticals, Inc.
    MODEYSO is indicated for treating adult and pediatric patients aged 1 year and older with progressive diffuse midline glioma harboring an H3 K27M mutation, following prior therapy. Approval is under accelerated conditions based on response rates, with continued approval potentially requiring further clinical confirmation.
    Medication Details
    Drug Interactions

  • rylaze

    (asparaginase erwinia chrysanthemi (recombinant)-rywn)
    Jazz Pharmaceuticals, Inc.
    RYLAZE is indicated for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in patients aged 1 month and older who are hypersensitive to E. coli-derived asparaginase, as part of a multi-agent chemotherapy regimen.
    Medication Details
    Drug Interactions

  • vyxeos

    ((daunorubicin and cytarabine) liposome)
    Jazz Pharmaceuticals, Inc.
    VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients aged 1 year and older.
    Medication Details
    Drug Interactions

  • xywav

    (calcium, magnesium, potassium, and sodium oxybates)
    Jazz Pharmaceuticals, Inc.
    XYWAV is indicated for treating cataplexy and excessive daytime sleepiness in patients aged 7 and older with narcolepsy, as well as for the treatment of idiopathic hypersomnia in adults.
    Medication Details
    Drug Interactions

  • ziihera

    (zanidatamab-hrii)
    Jazz Pharmaceuticals, Inc.
    ZIIHERA is indicated for treating adults with unresectable or metastatic HER2-positive biliary tract cancer (BTC) that has been previously treated, as determined by an FDA-approved test. This indication is based on accelerated approval due to overall response rate and duration of response.
    Medication Details
    Drug Interactions